Blueprint Medicines Corp (NASDAQ:BPMC) Director Nicholas Lydon sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $84.77, for a total transaction of $2,119,250.00. Following the completion of the sale, the director now directly owns 166,527 shares of the company’s stock, valued at $14,116,493.79.
Technical Stock Analysis
Blueprint Medicines Corporation (NASDAQ:BPMC), a Healthcare sector firm, traded 396997 shares in last trading session and stock tumbled -2.47% with closing price of $92.82 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Blueprint Medicines Corporation (NASDAQ:BPMC)’s profitability or to compare the efficiency of different investments, hence, BPMC return on investment (ROI) is -59.00%.
52-Week Range are valuable stats for watching Blueprint Medicines Corporation (NASDAQ:BPMC)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Blueprint Medicines Corporation (NASDAQ:BPMC)’s stock value has moved between $44.63 – 100.89 in last one year.
Analysts mean target price for Blueprint Medicines Corporation (NASDAQ:BPMC) is $109.38 while analysts mean recommendation is 1.40.
Its weekly performance is -1.72% while year to date (YTD) performance is 72.18%.
Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Blueprint Medicines Corporation (NASDAQ:BPMC)’s EPS growth this year is -37.60%. For best decision making investors should look at Blueprint Medicines Corporation (NASDAQ:BPMC)’s EPS growth for next year stands at -3.50%.